Compare Agilent Technologies Inc (A) vs Moderna, Inc. (MRNA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Agilent Technologies Inc vs Moderna, Inc. — how do they compare? Agilent Technologies Inc trades at $128.5 (market cap $37.04B), while Moderna, Inc. trades at $73.6 (market cap $31.65B). The key difference: Agilent Technologies Inc is the larger of the two by market cap, and Agilent Technologies Inc pays a 0.78% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| A | MRNA | |
|---|---|---|
Market Cap | $37.04B | $31.65B |
Sector | Health | Health |
52-Week High | $157.20 | $81.80 |
52-Week Low | $110.24 | $22.36 |
Enterprise Value | $38.59B | $27.74B |
Dividend Yield | 0.78% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Agilent Technologies Inc
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
